The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00090116

Enrollment

400

Registered

2004-08-26

Start date

2003-03-31

Completion date

2005-03-31

Last updated

2012-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

Neramexane, NMDA receptor antagonist, Memory Loss, Alzheimer Disease

Brief summary

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

Interventions

DRUGNeramexane

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of moderate to severe Alzheimer's disease; * ambulatory patients

Exclusion criteria

* folate deficiency; * clinically significant central nervous system disease other than Alzheimer's disease; * clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026